The GLP-1 receptor appears throughout the brain, pancreas, and gastrointestinal tract, making it one of the most versatile metabolic targets available
NHS availability is unlikely before the mid-to-late 2020s at the earliest, as retatrutide must first complete phase 3 trials, receive MHRA marketing authorisation, and undergo a NICE health technology appraisal to assess its clinical and cost-effectiveness
Now I can lift really heavy and my elbows don't hurt
The wider history should include recent illness, fever, surgery, anaesthesia, psychological stress, thyroid disease, menstrual blood loss, previous bariatric surgery, other medications and a personal or family history of pattern hair loss
This section discusses general scientific concepts and does not constitute an endorsement of any specific product or clinical claim